Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting of conditional share awards under the GlaxoSmithKline Share Value Plan (SVP).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on equity compensation events. The fair market values at the point of vesting on February 24, 2014, were:
- Ordinary Share: £16.83
- American Depositary Share (ADS): US$55.75
Material Changes
The material event reported is the conclusion of the three-year vesting period for 2011 SVP awards, which commenced on February 24, 2011. The vesting occurred on February 24, 2014, for individuals who were subsequently appointed as PDMRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Vesting of conditional share awards made in 2011.
- Participants: Four PDMRs received vested shares: Mr. R. Connor (8,230 shares), Mr. J. Ford (5,740 shares), Mr. P. Thomson (10,050 shares), and Mrs. V. Whyte (10,050 shares).
- Valuation: Transactions were valued at £16.83 per Ordinary Share and US$55.75 per ADS on the vesting date.
- Notification Date: The Company and PDMRs were advised of these transactions on February 25, 2014.